Trial Profile
A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira vaccine in Healthy 'Adults' aged greater than or equal to 18 to < 60 years and in Healthy 'Older Adults' aged greater than or equal to 60 years for the 2008/2009 Northern Hemisphere Influenza Season.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2012
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Afluria) (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors CSL
- 01 Aug 2011 New trial record